Search research articles
Contact Us
Filters
Showing results (31-40 of 98) with videos related to
Page
of 10
Sort By:
Expert Review of Anticancer Therapy
|
August 18, 2020
Outcomes with anti-EGFR monoclonal antibodies in metastatic and recurrent anal squamous cell carcinoma
Jane E Rogers, Alexandre A A Jácome, Aki Ohinata, et al.
Advances in Radiation Oncology
|
February 23, 2026
Can Patients With Recurrent or Primary Squamous Cell Carcinoma of the Anus in a Previously Irradiated Pelvis Receive Definitive Reirradiation?
Jordan McDonald, Ethan P Damron, Prajnan Das, et al.
The Journal of Thoracic and Cardiovascular Surgery
|
September 10, 2023
Factors associated with receipt of pulmonary metastasectomy in patients with lung-limited metastatic colorectal cancer: Disparities in care and impact on overall survival
Mara B Antonoff, Naishu Kui, Ryan Sun, et al.
Cancers
|
March 28, 2025
Clinicopathologic Features Associated with Survival for Immune Checkpoint Blockade in Patients with Metastatic Anal Cancer
Arjun S Peddireddy, Ryan Huey, Robert A Wolff, et al.
British Journal of Cancer
|
June 9, 2016
Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer
Michael S Lee, Elizabeth J McGuffey, Jeffrey S Morris, et al.
NPJ Precision Oncology
|
February 5, 2025
BRAF mutant appendiceal adenocarcinoma differs from colorectal cancer but responds to BRAF-targeted therapy
Vinay K Pattalachinti, Emaan Haque, Mahmoud Yousef, et al.
Clinical Colorectal Cancer
|
September 13, 2018
Prognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic Characteristics
Maliha Khan, Jonathan M Loree, Shailesh M Advani, et al.
Cancer Research
|
August 1, 2022
Targeting RAS Mutant Colorectal Cancer with Dual Inhibition of MEK and CDK4/6
Alexey V Sorokin, Preeti Kanikarla Marie, Lea Bitner, et al.
The Oncologist
|
June 16, 2020
Phase I Study of Ramucirumab Plus Merestinib in Previously Treated Metastatic Colorectal Cancer: Safety, Preliminary Efficacy, and Pharmacokinetic Findings
Mansoor Saleh, Philippe A Cassier, Lauriane Eberst, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education
|
March 12, 2024
Institution-Wide Retreats Foster Organizational Learning and Action at a Comprehensive Cancer Center
Benjamin R Schrank, John A Fuller, Colleen M Gallagher, et al.
Page
of 10
Search research articles
Search
Showing results (31-40 of 98) with videos related to
Sort By:
Page
of 10
Expert Review of Anticancer Therapy
|
August 18, 2020
Outcomes with anti-EGFR monoclonal antibodies in metastatic and recurrent anal squamous cell carcinoma
Jane E Rogers, Alexandre A A Jácome, Aki Ohinata, et al.
Advances in Radiation Oncology
|
February 23, 2026
Can Patients With Recurrent or Primary Squamous Cell Carcinoma of the Anus in a Previously Irradiated Pelvis Receive Definitive Reirradiation?
Jordan McDonald, Ethan P Damron, Prajnan Das, et al.
The Journal of Thoracic and Cardiovascular Surgery
|
September 10, 2023
Factors associated with receipt of pulmonary metastasectomy in patients with lung-limited metastatic colorectal cancer: Disparities in care and impact on overall survival
Mara B Antonoff, Naishu Kui, Ryan Sun, et al.
Cancers
|
March 28, 2025
Clinicopathologic Features Associated with Survival for Immune Checkpoint Blockade in Patients with Metastatic Anal Cancer
Arjun S Peddireddy, Ryan Huey, Robert A Wolff, et al.
British Journal of Cancer
|
June 9, 2016
Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer
Michael S Lee, Elizabeth J McGuffey, Jeffrey S Morris, et al.
NPJ Precision Oncology
|
February 5, 2025
BRAF mutant appendiceal adenocarcinoma differs from colorectal cancer but responds to BRAF-targeted therapy
Vinay K Pattalachinti, Emaan Haque, Mahmoud Yousef, et al.
Clinical Colorectal Cancer
|
September 13, 2018
Prognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic Characteristics
Maliha Khan, Jonathan M Loree, Shailesh M Advani, et al.
Cancer Research
|
August 1, 2022
Targeting RAS Mutant Colorectal Cancer with Dual Inhibition of MEK and CDK4/6
Alexey V Sorokin, Preeti Kanikarla Marie, Lea Bitner, et al.
The Oncologist
|
June 16, 2020
Phase I Study of Ramucirumab Plus Merestinib in Previously Treated Metastatic Colorectal Cancer: Safety, Preliminary Efficacy, and Pharmacokinetic Findings
Mansoor Saleh, Philippe A Cassier, Lauriane Eberst, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education
|
March 12, 2024
Institution-Wide Retreats Foster Organizational Learning and Action at a Comprehensive Cancer Center
Benjamin R Schrank, John A Fuller, Colleen M Gallagher, et al.
Page
of 10